{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:55:03Z","timestamp":1790805303149,"version":"4.1.0"},"reference-count":57,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Drug development for neurodegenerative diseases such as Alzheimer\u2019s disease, Parkinson\u2019s disease, and Huntington\u2019s disease has challenging difficulties due to the pharmacokinetic impermeability based on the blood-brain barrier (BBB) as well as the blurriness of pharmacodynamic targets based on their unclarified pathogenesis and complicated progression mechanisms. Thus, in order to produce innovative central nervous system (CNS) agents for patients suffering from CNS diseases, effective, selective delivery of CNS agents into the brain across the BBB should be developed. Currently, proteolysis-targeting chimeras (PROTACs) attract rising attention as a new modality to degrade arbitrary intracellular proteins by the ubiquitin-proteasome system. The internalizations of peptide-based PROTACs by cell-penetrating peptides and that of small molecule-based PROTACs through passive diffusion lack cell selectivity. Therefore, these approaches may bring off-target side effects due to wrong distribution. Furthermore, efflux transporters such as multiple drug resistance 1 (MDR1) expressed at the BBB might interrupt the entry of small molecule-based PROTACs into the brain. Nonetheless, intelligent delivery using machinery systems to absorb the nutrition into the brain for homeostasis, such as carrier-mediated transport (CMT) or receptor-mediated transcytosis (RMT), can be established. PROTACs with N-containing groups that are recognized by the proton-coupled organic cation antiporter might cross the BBB through CMT. PROTAC-antibody conjugates (PACs) might cross the BBB through RMT. Subsequently, such small molecule-based PROTACs released in the brain interstitial fluid would be transported into cells such as neurons through passive diffusion and then demonstrate arbitrary protein degradation. In this review, I introduce the potential and advantages of PROTAC delivery into the brain across the BBB through CMT or RMT using PACs in a non-invasive way.<\/jats:p>","DOI":"10.3390\/antib12030043","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T02:11:22Z","timestamp":1687831882000},"page":"43","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier"],"prefix":"10.3390","volume":"12","author":[{"given":"Toshihiko","family":"Tashima","sequence":"first","affiliation":[{"name":"Tashima Laboratories of Arts and Sciences, 1239-5 Toriyama-cho, Kohoku-ku, Yokohama 222-0035, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem. Funct."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","article-title":"PROTACs: Great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.tins.2020.12.002","article-title":"Blood-Brain Barrier Dynamics to Maintain Brain Homeostasis","volume":"44","author":"Segarra","year":"2021","journal-title":"Trends Neurosci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature09522","article-title":"Pericytes regulate the blood-brain barrier","volume":"468","author":"Armulik","year":"2010","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1349-7006.2007.00538.x","article-title":"Mechanism of multidrug recognition by MDR1\/ABCB1","volume":"98","author":"Kimura","year":"2007","journal-title":"Cancer Sci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tashima, T. (2022). Brain Cancer Chemotherapy through a Delivery System across the Blood-Brain Barrier into the Brain Based on Receptor-Mediated Transcytosis Using Monoclonal Antibody Conjugates. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071597"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tashima, T. (2022). Delivery of Intravenously Administered Antibodies Targeting Alzheimer\u2019s Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020411"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1016\/j.bmc.2015.06.022","article-title":"Intriguing possibilities and beneficial aspects of transporter-conscious drug design","volume":"23","author":"Tashima","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1248\/cpb.c19-00854","article-title":"Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood\u2013Brain Barrier Using Receptor-Mediated Transcytosis","volume":"68","author":"Tashima","year":"2020","journal-title":"Chem. Pharm. Bull."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.tcb.2013.12.003","article-title":"Perilous journey: A tour of the ubiquitin-proteasome system","volume":"24","author":"Kleiger","year":"2014","journal-title":"Trends Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","article-title":"Cellular quality control by the ubiquitin-proteasome system and autophagy","volume":"366","author":"Pohl","year":"2019","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11269","DOI":"10.1021\/acs.chemrev.7b00077","article-title":"Small-Molecule Modulation of Protein Homeostasis","volume":"117","author":"Burslem","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1248\/yakushi.18-00113","article-title":"Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy","volume":"138","author":"Ohoka","year":"2018","journal-title":"Yakugaku Zasshi"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: A critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor. Target Antitumor Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13029","DOI":"10.1021\/acs.jmedchem.2c00877","article-title":"Linker-dependent folding rationalizes PROTAC cell permeability","volume":"65","author":"Poongavanam","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1021\/acsomega.2c07717","article-title":"Predictive Modeling of PROTAC Cell Permeability with Machine Learning","volume":"8","author":"Poongavanam","year":"2022","journal-title":"ACS Omega"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2014.10.006","article-title":"Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus","volume":"453","author":"Montrose","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","article-title":"Chemical genetic control of protein levels: Selective in vivo targeted degradation","volume":"12","author":"Schneekloth","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.chembiol.2016.02.016","article-title":"Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation","volume":"23","author":"Chu","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a Keap1-dependent peptide PROTAC to knockdown tau by ubiquitination-proteasome degradation pathway","volume":"146","author":"Lu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.chembiol.2020.03.010","article-title":"Specific Knockdown of \u03b1-Synuclein by Peptide Directed Proteasome Degradation Rescued Its Associated Neurotoxicity","volume":"27","author":"Qu","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lee, J., Lee, Y., Jung, Y.M., Park, J.H., Yoo, H.S., and Park, J. (2022). Discovery of E3 Ligase Ligands for Target Protein Degradation. Molecules, 27.","DOI":"10.3390\/molecules27196515"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric Molecules That Target Proteins to the Skp1-Cullin-F Box Complex for Ubiquitination and Degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted Intracellular Protein Degradation Induced by a Small Molecule: En Route to Chemical Proteomics","volume":"18","author":"Smith","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pedrucci, F., Pappalardo, C., Marzaro, G., Ferri, N., Ferlin, A., and De Toni, L. (2022). Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126630"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chambers-Richards, T., Chireh, B., and D\u2019Arcy, C. (2022). Unmet health care needs: Factors predicting satisfaction with health care services among community-dwelling Canadians living with neurological conditions. BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-08611-0"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12640-020-00185-1","article-title":"Exploring the Promise of Targeting Ubiquitin-Proteasome System to Combat Alzheimer\u2019s Disease","volume":"38","author":"Mamun","year":"2020","journal-title":"Neurotox. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pneurobio.2013.03.001","article-title":"Tau degradation: The ubiquitin\u2013proteasome system versus the autophagy-lysosome system","volume":"105","author":"Lee","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e45457","DOI":"10.7554\/eLife.45457","article-title":"Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models","volume":"8","author":"Silva","year":"2019","journal-title":"eLife"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: The rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"eabn2707","DOI":"10.1126\/scisignal.abn2707","article-title":"The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells","volume":"15","author":"Kurimchak","year":"2022","journal-title":"Sci. Signal."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Vagrys, D., Davidson, J., Chen, I., Hubbard, R.E., and Davis, B. (2020). Exploring IDP\u2013Ligand Interactions: Tau K18 as a Test Case. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155257"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A Novel Small-molecule PROTAC Selectively Promotes Tau Clearance to Improve Cognitive Functions in Alzheimer-like Models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"26308","DOI":"10.1021\/acsomega.2c02130","article-title":"Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer\u2019s disease","volume":"7","author":"Liang","year":"2022","journal-title":"ACS Omega"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acsmedchemlett.0c00192","article-title":"PROTAC Compounds Targeting \u03b1-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer\u2019s and Parkinson\u2019s Diseases","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_37","unstructured":"Crew, A.P., Dong, H., Berlin, M., and Sparks, S.M. (2020). Proteolysis Targeting Chimeric (PROTAC) Compound with E3 Ubiquitin Ligase Binding Activity and Targeting Alpha-Synuclein Protein for Treating Neurovegetative Diseases. (WO 2020\/041331 A1)."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7615","DOI":"10.1038\/s41598-019-44151-0","article-title":"Molecular mechanisms of heterogeneous oligomerization of huntingtin proteins","volume":"9","author":"Bonfanti","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Irfan, Z., Khanam, S., Karmakar, V., Firdous, S.M., El Khier, B.S.I.A., Khan, I., Rehman, M.U., and Khan, A. (2022). Pathogenesis of Huntington\u2019s Disease: An Emphasis on Molecular Pathways and Prevention by Natural Remedies. Brain Sci., 12.","DOI":"10.3390\/brainsci12101389"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11530","DOI":"10.1002\/anie.201706529","article-title":"Discovery of Small Molecules that Induce the Degradation of Huntingtin","volume":"56","author":"Tomoshige","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","article-title":"Blood\u2013brain barrier breakdown is an early biomarker of human cognitive dysfunction","volume":"25","author":"Nation","year":"2019","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.ymgme.2018.12.205","article-title":"Non-clinical evaluation of a blood-brain barrier-penetrating enzyme for the treatment of mucopolysaccharidosis type I","volume":"126","author":"Kida","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1\/2 Trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader-antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acs.jmedchem.2c01791","article-title":"Degrader-Antibody Conjugates: Emerging New Modality","volume":"66","author":"Hong","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1182\/bloodadvances.2019000507","article-title":"Moxetumomab pasudotox for hairy cell leukemia: Preclinical development to FDA approval","volume":"3","author":"Lin","year":"2019","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"126907","DOI":"10.1016\/j.bmcl.2019.126907","article-title":"Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ER\u03b1)","volume":"30","author":"Dragovich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/acs.jmedchem.0c01845","article-title":"Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties","volume":"64","author":"Dragovich","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1021\/acs.jmedchem.0c01846","article-title":"Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy","volume":"64","author":"Dragovich","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_51","first-page":"634","article-title":"The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"Mankarious","year":"1988","journal-title":"J. Lab. Clin. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fcell.2021.805336","article-title":"Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles","volume":"9","author":"Juan","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Cimas, F.J., Niza, E., Juan, A., Noblejas-L\u00f3pez, M.d.M., Bravo, I., Lara-Sanchez, A., Alonso-Moreno, C., and Oca\u00f1a, A. (2020). Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12100986"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1083\/jcb.201008117","article-title":"Local clustering of transferrin receptors promotes clathrin-coated pit initiation","volume":"191","author":"Liu","year":"2010","journal-title":"J. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1128\/JVI.07194-11","article-title":"Limited Transferrin Receptor Clustering Allows Rapid Diffusion of Canine Parvovirus into Clathrin Endocytic Structures","volume":"86","author":"Cureton","year":"2012","journal-title":"J. Virol."},{"key":"ref_56","unstructured":"Laughlin, C.D., and D\u2019Aquili, E.G. (1974). Biogenetic Structuralism, Columbia University Press."},{"key":"ref_57","first-page":"420","article-title":"Biogenetic Structuralism","volume":"49","author":"Leavy","year":"1976","journal-title":"Yale J. Biol. Med."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/12\/3\/43\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:01:09Z","timestamp":1760126469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/12\/3\/43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["antib12030043"],"URL":"https:\/\/doi.org\/10.3390\/antib12030043","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]}}}